肯雅塔国家医院急性髓系白血病患者药物不良反应评估

IF 0.9 4区 医学 Q4 ONCOLOGY
Mari Heho, Amsalu Degu, Calvin A Omolo
{"title":"肯雅塔国家医院急性髓系白血病患者药物不良反应评估","authors":"Mari Heho, Amsalu Degu, Calvin A Omolo","doi":"10.1177/10781552251352453","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundAcute Myeloid leukaemia (AML) chemotherapy is linked to a considerable adverse drug reaction (ADRs). However, data regarding the ADRs in AML patients receiving chemotherapy in Kenya is scarce. This study aimed to assess the adverse drug reactions among AML patients treated at Kenyatta National Hospital (KNH).MethodsA one-arm retrospective cohort study design was used to assess ADRs among eligible AML patients who received treatment at KNH between 1st January 2018 and 31st December 2023. A data abstraction tool was used to collect socio-demographics, comorbidities, the treatment regimen, and chemotherapy-related ADRs. The CTCAE v3.0 grading system and the modified Schumock and Thornton Scale were used to evaluate the severity and preventability of ADRs, respectively. The data collected was analysed using the SPSS version 29.0.01 software. Mean and median were used to report the age of participants, while other socio-demographic variables and adverse drug reactions were reported as percentages and frequencies.ResultsThe prevalence of ADRs in this study was 96.7%, with a total of 123 ADRs recorded. The main adverse reactions observed were neutropenia (18%), thrombocytopenia (16.3%), anaemia (14.6%), and liver damage (10.6%). The majority of the ADRs recorded were of moderate severity (40.7%) and non-preventable (59.3%).ConclusionThe prevalence of ADRs in AML patients was high. The most frequently reported ADR was neutropenia. The majority of ADRs were moderate severity level and non-preventable.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251352453"},"PeriodicalIF":0.9000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessment of adverse drug reactions among acute myeloid leukaemia patients at Kenyatta National Hospital.\",\"authors\":\"Mari Heho, Amsalu Degu, Calvin A Omolo\",\"doi\":\"10.1177/10781552251352453\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>BackgroundAcute Myeloid leukaemia (AML) chemotherapy is linked to a considerable adverse drug reaction (ADRs). However, data regarding the ADRs in AML patients receiving chemotherapy in Kenya is scarce. This study aimed to assess the adverse drug reactions among AML patients treated at Kenyatta National Hospital (KNH).MethodsA one-arm retrospective cohort study design was used to assess ADRs among eligible AML patients who received treatment at KNH between 1st January 2018 and 31st December 2023. A data abstraction tool was used to collect socio-demographics, comorbidities, the treatment regimen, and chemotherapy-related ADRs. The CTCAE v3.0 grading system and the modified Schumock and Thornton Scale were used to evaluate the severity and preventability of ADRs, respectively. The data collected was analysed using the SPSS version 29.0.01 software. Mean and median were used to report the age of participants, while other socio-demographic variables and adverse drug reactions were reported as percentages and frequencies.ResultsThe prevalence of ADRs in this study was 96.7%, with a total of 123 ADRs recorded. The main adverse reactions observed were neutropenia (18%), thrombocytopenia (16.3%), anaemia (14.6%), and liver damage (10.6%). The majority of the ADRs recorded were of moderate severity (40.7%) and non-preventable (59.3%).ConclusionThe prevalence of ADRs in AML patients was high. The most frequently reported ADR was neutropenia. The majority of ADRs were moderate severity level and non-preventable.</p>\",\"PeriodicalId\":16637,\"journal\":{\"name\":\"Journal of Oncology Pharmacy Practice\",\"volume\":\" \",\"pages\":\"10781552251352453\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Oncology Pharmacy Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10781552251352453\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552251352453","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:急性髓性白血病(AML)化疗与相当大的药物不良反应(adr)有关。然而,关于在肯尼亚接受化疗的AML患者的不良反应的数据很少。本研究旨在评估在肯雅塔国家医院(KNH)治疗的AML患者的药物不良反应。方法采用单臂回顾性队列研究设计,评估2018年1月1日至2023年12月31日在KNH接受治疗的符合条件的AML患者的不良反应。使用数据抽象工具收集社会人口统计学、合并症、治疗方案和化疗相关不良反应。采用CTCAE v3.0评分体系和改良的Schumock和Thornton量表分别评价不良反应的严重程度和可预防性。采用SPSS 29.0.01版软件对数据进行分析。平均值和中位数用于报告参与者的年龄,而其他社会人口变量和药物不良反应以百分比和频率报告。结果本组adr发生率为96.7%,共记录123例adr。观察到的主要不良反应为中性粒细胞减少(18%)、血小板减少(16.3%)、贫血(14.6%)和肝损害(10.6%)。大多数adr记录为中度(40.7%)和不可预防(59.3%)。结论AML患者不良反应发生率较高。最常见的不良反应是中性粒细胞减少症。大多数不良反应的严重程度为中等,不可预防。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Assessment of adverse drug reactions among acute myeloid leukaemia patients at Kenyatta National Hospital.

BackgroundAcute Myeloid leukaemia (AML) chemotherapy is linked to a considerable adverse drug reaction (ADRs). However, data regarding the ADRs in AML patients receiving chemotherapy in Kenya is scarce. This study aimed to assess the adverse drug reactions among AML patients treated at Kenyatta National Hospital (KNH).MethodsA one-arm retrospective cohort study design was used to assess ADRs among eligible AML patients who received treatment at KNH between 1st January 2018 and 31st December 2023. A data abstraction tool was used to collect socio-demographics, comorbidities, the treatment regimen, and chemotherapy-related ADRs. The CTCAE v3.0 grading system and the modified Schumock and Thornton Scale were used to evaluate the severity and preventability of ADRs, respectively. The data collected was analysed using the SPSS version 29.0.01 software. Mean and median were used to report the age of participants, while other socio-demographic variables and adverse drug reactions were reported as percentages and frequencies.ResultsThe prevalence of ADRs in this study was 96.7%, with a total of 123 ADRs recorded. The main adverse reactions observed were neutropenia (18%), thrombocytopenia (16.3%), anaemia (14.6%), and liver damage (10.6%). The majority of the ADRs recorded were of moderate severity (40.7%) and non-preventable (59.3%).ConclusionThe prevalence of ADRs in AML patients was high. The most frequently reported ADR was neutropenia. The majority of ADRs were moderate severity level and non-preventable.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.70
自引率
7.70%
发文量
276
期刊介绍: Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信